Tisotumab Vedotin Humax-tf-adc · Tivdak

Antibody–drug conjugate

Approvedregulatory verdict

Evidence outlook

Approved: Cervical Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 2 · investigational in the US

Also approved (3)
CN
  • Adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
Product first approved 2026biospace.com
EU
  • Tivdak as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy (see section 5.1).
Product first approved 2025EMA
JP
  • Treatment of advanced or recurrent cervical cancer that has progressed after cancer chemotherapy
Product first approved 2025PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Cervical Cancer
Phase 2 (5)
Cervical Cancer
Non-Small Cell Lung Cancer
NCT03245736 · Seagen Inc.
2017-08-23 – 2019-01-10 · Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer, Esophagus Cancer, Lung Cancer, Nonsmall Cell, Squamous Cell Carcinoma of the Head and Neck
What this study did
Other / comorbidity
NCT07672782 · GOG Foundation
2026-11 – 2029-12 · Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva
What this study did
NCT03657043 · Seagen Inc.
2019-03-20 – 2022-02-08 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
Phase 1/2 (4)
Cervical Cancer
NCT03786081 · Seagen, a wholly owned subsidiary of Pfizer
2019-02-27 – 2026-03-19 · Cervical Cancer
What this study did
Non-Small Cell Lung Cancer
NCT02552121 · Seagen Inc.
2015-11-30 – 2017-12-13 · Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer (NSCLC)
What this study did
Other / comorbidity
NCT03913741 · Genmab
2019-02-27 – 2021-10-30 · Solid Tumor
What this study did
Phase 1 (1)
Other / comorbidity
NCT05866354 · Zai Lab (Shanghai) Co., Ltd.
2023-06-16 – 2023-11-02 · Solid Malignancies
What this study did
Phase 4 (1)
Cervical Cancer
NCT06952660 · Pfizer
2025-05-07 – 2028-12-13 · Cervical Cancer
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Cervical Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tisotumab Vedotin Humax-Tf-Adc (Tivdak): this drugApprovedAntibody–drug conjugateTissue Factor (TF)Partial signal
NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7)
NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sutantatug EnvedotinPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ALE.P02
Phase 1/2(overall)
Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
SHR-4375
Phase 1/2(overall)
Antibody–drug conjugateTissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tivdak (Tisotumab Vedotin Humax-tf-adc) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Phase 4Cervical CancerRecruiting
Est. primary completion 2028-12-13 · NCT06952660 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 2Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma VulvaNot yet recruiting
Est. primary completion 2029-03 · NCT07672782 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 June 2026ApprovalNMPA approves TIVDAK for recurrent or metastatic cervical cancer
CN, NMPA · Source ↗
1 September 2025ApprovalTIVDAK approved in Hong Kong
HK, Hong Kong Department of Health · Source ↗